UK markets closed

GenSight Biologics S.A. (0RIM.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.3505-0.0095 (-2.64%)
At close: 04:12PM BST
Full screen
Previous close0.3600
Open0.3900
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.3505 - 0.3900
52-week range0.3280 - 2.5300
Volume701
Avg. volume2,025
Market cap9.972M
Beta (5Y monthly)2.12
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    GenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates

    PARIS, June 20, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the renegotiation of certain financial obligations, securing its financial position and improving short-term flexibility. The Company also provided operational updates.

  • Business Wire

    GenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings

    PARIS, June 04, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its participation at key medical and stakeholder meetings in the remainder of 2024.

  • Business Wire

    GenSight Biologics Appoints William Monteith to its Board of Directors

    PARIS, June 03, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the appointment of William Monteith to its Board of Directors. Mr. Monteith joined as an independent Director after existing Board members approved his nomination at the meeting on May 29, 2